IN2015DN03070A - - Google Patents

Info

Publication number
IN2015DN03070A
IN2015DN03070A IN3070DEN2015A IN2015DN03070A IN 2015DN03070 A IN2015DN03070 A IN 2015DN03070A IN 3070DEN2015 A IN3070DEN2015 A IN 3070DEN2015A IN 2015DN03070 A IN2015DN03070 A IN 2015DN03070A
Authority
IN
India
Prior art keywords
polypeptides
optimized
eliciting
immune response
influenza virus
Prior art date
Application number
Other languages
English (en)
Inventor
Ted M Ross
Jr Donald M Carter
Corey J Crevar
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of IN2015DN03070A publication Critical patent/IN2015DN03070A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN3070DEN2015 2012-11-27 2013-11-27 IN2015DN03070A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730186P 2012-11-27 2012-11-27
PCT/US2013/072279 WO2014085616A1 (en) 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for h1n1 influenza

Publications (1)

Publication Number Publication Date
IN2015DN03070A true IN2015DN03070A (OSRAM) 2015-10-02

Family

ID=50773495

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3070DEN2015 IN2015DN03070A (OSRAM) 2012-11-27 2013-11-27

Country Status (13)

Country Link
US (3) US9309290B2 (OSRAM)
EP (1) EP2925773B1 (OSRAM)
JP (2) JP2016505538A (OSRAM)
KR (1) KR20150089005A (OSRAM)
CN (1) CN104797594A (OSRAM)
AU (2) AU2013352179B2 (OSRAM)
CA (1) CA2891682A1 (OSRAM)
HK (1) HK1212708A1 (OSRAM)
IN (1) IN2015DN03070A (OSRAM)
MX (1) MX2015005056A (OSRAM)
RU (1) RU2015124805A (OSRAM)
SG (1) SG11201503989PA (OSRAM)
WO (1) WO2014085616A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すh1n1インフルエンザの抗原
KR20150004800A (ko) 2012-03-30 2015-01-13 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 H5n1 및 h1n1 인플루엔자 바이러스를 위한 계산적으로 최적화된 넓게 반응하는 항원
AU2015364253B2 (en) * 2014-12-19 2020-01-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
CN108290932A (zh) * 2015-06-09 2018-07-17 圣诺菲·帕斯图尔公司 优化编码工程改造的流感蛋白的核苷酸序列的方法
IL263416B2 (en) 2016-06-03 2024-10-01 Sanofi Pasteur Inc Modification of transgenic influenza hemagglutinin polypeptides

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000885A2 (en) 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
CN101227920A (zh) 2005-07-19 2008-07-23 陶氏环球技术公司 重组流感疫苗
WO2007072214A2 (en) 2005-12-19 2007-06-28 Novartis Vaccines And Diagnostics Srl Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs)
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
CA2762042C (en) * 2009-06-24 2012-11-20 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すh1n1インフルエンザの抗原
HK1203524A1 (en) 2012-02-07 2015-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
AU2013221877B2 (en) 2012-02-13 2017-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
KR20150004800A (ko) * 2012-03-30 2015-01-13 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 H5n1 및 h1n1 인플루엔자 바이러스를 위한 계산적으로 최적화된 넓게 반응하는 항원

Also Published As

Publication number Publication date
US9566328B2 (en) 2017-02-14
EP2925773A4 (en) 2016-06-08
EP2925773A1 (en) 2015-10-07
HK1212708A1 (zh) 2016-06-17
AU2018201876A1 (en) 2018-04-12
US9309290B2 (en) 2016-04-12
CA2891682A1 (en) 2014-06-05
WO2014085616A1 (en) 2014-06-05
US20160166677A1 (en) 2016-06-16
MX2015005056A (es) 2015-07-23
AU2013352179A8 (en) 2015-05-28
CN104797594A (zh) 2015-07-22
SG11201503989PA (en) 2015-06-29
EP2925773B1 (en) 2018-12-26
AU2013352179B2 (en) 2017-12-21
KR20150089005A (ko) 2015-08-04
RU2015124805A (ru) 2017-01-13
US20170114102A1 (en) 2017-04-27
US20140147459A1 (en) 2014-05-29
JP2016505538A (ja) 2016-02-25
AU2013352179A1 (en) 2015-05-14
US10017544B2 (en) 2018-07-10
JP2018183149A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
IN2015DN03070A (OSRAM)
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EA201891712A2 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
IN2015DN03206A (OSRAM)
WO2012082803A3 (en) Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
PL406631A1 (pl) Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie
TN2010000332A1 (en) Recombinant influenza virus-like particles (vlps)produced in transgenic plants expressing hemagglutinin
RU2010121411A (ru) Рекомбинантная вакцина против вируса "свиного" гриппа h1n1 и способ ее получения